ClinicalTrials.Veeva

Menu

Motiva Implants® Post-Approval Study (Motiva PAS)

M

Motiva

Status

Not yet enrolling

Conditions

Breast Implant

Treatments

Device: Silicone gel-filled breast implants - Motiva Implants®
Other: Aesthetic Surgery

Study type

Interventional

Funder types

Industry

Identifiers

NCT06938399
CIP-001005
P230005 (Other Identifier)

Details and patient eligibility

About

This study examines the general post-market use and safety of Motiva Implants® and gathers and assesses selected safety and effectiveness data about their post market performance and experience.

Full description

Prospective, non-randomized, multicenter study including baseline (preoperative), operative, and postoperative data collection annually Years 1-10.

Enrollment

2,400 estimated patients

Sex

Female

Ages

22+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria Motiva Implants®:

  • Female
  • Patient is seeking one of the following procedures: -Primary Breast Augmentation: age 22 and over, indicated to increase breast size -Revision Breast Augmentation: removal and replacement of breast implants (revision) to correct or improve the results of a previous breast augmentation
  • Patient has adequate tissue available to cover implant(s)
  • Willingness to follow all study requirements
  • Signs an Informed Consent
  • Agrees to have device returned to the Sponsor, if explanted
  • Willing to undergo Computed Tomography Scan (CT), ultrasound, or MRI evaluation, if medically advised

Inclusion Criteria Control group:

  • Is 22 years of age or older
  • Female
  • Is a candidate for aesthetic surgery (such as liposuction, rhinoplasty, face-lift)
  • Signs an Informed Consent
  • Willingness to follow all study requirements

Exclusion Criteria Motiva Implants®:

  • Has any breast disease considered to be pre-malignant in one or both breasts or is reporting mutations in BRCA1 or BRCA2
  • Has inadequate or unsuitable tissue (e.g., due to radiation damage, ulceration, compromised vascularity, history of compromised wound healing)
  • Has an active infection anywhere in their body
  • Is pregnant or nursing, or has had a full-term pregnancy or lactated within 6 months of enrollment
  • Is taking any drugs that would interfere with blood clotting, or that might result in elevated risk and/or significant postoperative complications
  • Has any medical condition such as obesity (BMI >40), diabetes, autoimmune disease, chronic lung or severe cardiovascular disease that might result in unduly high surgical risk and/or significant postoperative complications
  • Has any connective tissue/autoimmune disorder or rheumatoid disease, such as systemic lupus erythematosus, discoid lupus, scleroderma, or rheumatoid arthritis, among others
  • Has a history of psychological characteristics that are unrealistic or unreasonable given the risks involved with the surgical procedure
  • Has been implanted with any non-FDA approved breast implant
  • Has been implanted with any silicone implant other than breast implants
  • HIV positive (based on medical history)
  • Has been diagnosed with Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL)

Exclusion Criteria Control group:

  • Has a history of silicone implants (anywhere in the body)
  • Plans to undergo silicone breast implant surgery during the course of the study
  • Has an active infection anywhere in their body
  • Has a history of cancer (except skin cancer)
  • Is taking any drugs that would interfere with blood clotting, or that might result in elevated risk and/or significant postoperative complications
  • Has any medical condition such as obesity (BMI >40), diabetes, autoimmune disease, chronic lung or severe cardiovascular disease that might result in unduly high surgical risk and/or significant postoperative complications
  • Has any connective tissue/autoimmune disorder or rheumatoid disease, such as systemic lupus erythematosus, discoid lupus, scleroderma, or rheumatoid arthritis, among others

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

2,400 participants in 3 patient groups

Primary Augmentation
Other group
Description:
Subjects age 22 and over, indicated to increase breast size
Treatment:
Device: Silicone gel-filled breast implants - Motiva Implants®
Revision Augmentation
Other group
Description:
Revision surgery to correct or improve the results of a previous breast augmentation
Treatment:
Device: Silicone gel-filled breast implants - Motiva Implants®
Control Group
Other group
Description:
Aesthetic procedure other than breast implant surgery
Treatment:
Other: Aesthetic Surgery

Trial contacts and locations

1

Loading...

Central trial contact

Sofia Chaves-Chen, PharmD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems